

Denis-Claude Roy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5229756/publications.pdf>

Version: 2024-02-01

124
papers

3,838
citations

236612

25
h-index

128067

60
g-index

128
all docs

128
docs citations

128
times ranked

5592
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 157-161.	2.0	13
2	Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1 safety and feasibility study. <i>Lancet Haematology</i> , 2020, 7, e134-e145.	2.2	138
3	Single UM171-expanded cord blood transplant can cure severe idiopathic aplastic anemia in absence of suitable donors. <i>European Journal of Haematology</i> , 2020, 105, 808-811.	1.1	3
4	Analysis of the COMPARE-AMI trial: First report of long-term safety of CD133+ cells. <i>International Journal of Cardiology</i> , 2020, 319, 32-35.	0.8	2
5	Single UM171-Expanded Cord Blood Transplants Support Robust T Cell Reconstitution with Low Rates of Severe Infections. <i>Stem Cells Translational Medicine</i> , 2020, 9, S8.	1.6	0
6	UM171 Expansion Overcomes Shortcomings of Cord Blood Transplantation While Maintaining Benefits. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S294-S295.	2.0	0
7	Myeloma Patients Relapsing after First Line Treatment with Tandem Auto/Allo Transplant or Auto Transplant Only Have Similar Outcomes.. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S228-S229.	2.0	0
8	ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia. <i>Leukemia</i> , 2020, 34, 1907-1923.	3.3	20
9	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020, 105, 47-58.	1.7	51
10	Stigma associated with parental depression or cancer: Impact on spouse and offspring's cortisol levels and socioemotional functioning. <i>Development and Psychopathology</i> , 2020, 32, 1822-1837.	1.4	3
11	Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating Functions. <i>Blood Cancer Discovery</i> , 2020, 1, 48-67.	2.6	1
12	Newly diagnosed multiple myeloma patients treated with tandem auto-allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only. <i>Clinical Transplantation</i> , 2020, 34, e14099.	0.8	4
13	Cellular therapy approaches harnessing the power of the immune system for personalized cancer treatment. <i>Seminars in Immunology</i> , 2019, 42, 101306.	2.7	17
14	Allodepleted T cell immunotherapy after haploidentical hematopoietic stem cell transplantation without severe acute graft-versus-host disease (GVHD) in the absence of GVHD prophylaxis. <i>British Journal of Haematology</i> , 2019, 186, 754-766.	1.2	20
15	Critical Role for TCR Signal Strength and MHC Specificity in ThPOK-Induced CD4 Helper Lineage Choice. <i>Journal of Immunology</i> , 2019, 202, 3211-3225.	0.4	5
16	Profound MRD negativity rates after frontline tandem autologous-allogeneic stem cell transplantation followed by bortezomib maintenance in high-risk or young myeloma patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e41-e42.	0.2	3
17	Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for fitness and chemosensitive disease. <i>Leukemia Research</i> , 2019, 79, 75-80.	0.4	8
18	Double-Negative T Cell Levels Correlate with Chronic Graft-versus-Host Disease Severity. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 19-25.	2.0	16

#	ARTICLE	IF	CITATIONS
19	Head-to-Head Comparison of Haploidentical HSCT Strategies for Hematologic Malignancies: Phase III Hatcy Study of T-Cell-Depleted HSCT with Adjunctive ATIR101 Versus T-Cell-Replete HSCT with Postâ€¢ransplant Cyclophosphamide. <i>Blood</i> , 2019, 134, 4464-4464.	0.6	0
20	Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors. <i>Blood</i> , 2019, 134, 592-592.	0.6	0
21	UM171 Modified Cord Blood Achieves Excellent Survival and Disease Control after 2 Years of Follow-up in High and Very High Risk Malignancies. <i>Blood</i> , 2019, 134, 3245-3245.	0.6	0
22	The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 521-534.	1.3	168
23	Membrane permeabilizing amphiphilic peptide delivers recombinant transcription factor and CRISPR-Cas9/Cpf1 ribonucleoproteins in hard-to-modify cells. <i>PLoS ONE</i> , 2018, 13, e0195558.	1.1	53
24	Bortezomib Consolidation after Frontline Auto-Allogeneic Transplant: Low Toxicity and Frequent Immunophenotypic Complete Responses in High-Risk or Young Myeloma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S250-S251.	2.0	0
25	Single UM171 Expanded Cord Blood Permits Transplantation of Better HLA Matched Cords with Excellent Gvhd Relapse Free Survival. <i>Blood</i> , 2018, 132, 4658-4658.	0.6	3
26	Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies. <i>Blood</i> , 2018, 132, 120-120.	0.6	1
27	Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation. <i>Blood</i> , 2018, 132, 4666-4666.	0.6	0
28	Depletion of Alloreactive T Cells after Haploidentical HSCT: Comparison of Outcomes for Ex Vivo Versus In Vivo Treatment Strategies. <i>Blood</i> , 2018, 132, 3474-3474.	0.6	0
29	Major vs minor histocompatibility antigens. <i>Blood</i> , 2017, 129, 664-666.	0.6	7
30	Add back of selectively depleted alloreactive T-cells retaining the full immune repertoire of mature T-cells improves event-free survival (GRFS) and overall survival in a T-cell depleted haploidentical HSCT. <i>Cytherapy</i> , 2017, 19, e2-e3.	0.3	0
31	Single UM171 Expanded Cord Blood Transplant Is Feasible, Safe, and Permits Transplantation of Better HLA Matched Cords with Very Low Transplant Related Mortality. <i>Blood</i> , 2017, 130, 658-658.	0.6	2
32	Favorable Long-Term Survival of Newly Diagnosed Multiple Myeloma Patients Using a Frontline Outpatient Tandem Approach. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S353-S354.	2.0	0
33	Bortezomib Consolidation after Allogeneic Nonmyeloablative Transplantation to Improve Outcome in Poor Prognosis Multiple Myeloma Patients: A Preliminary Safety Report. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S352-S353.	2.0	0
34	Impact of intracoronary injection of CD133+ bone marrow stem cells on coronary atherosclerotic progression in patients with STEMI. <i>Coronary Artery Disease</i> , 2016, 27, 5-12.	0.3	11
35	Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL. <i>Blood</i> , 2016, 128, 1226-1226.	0.6	29
36	Bortezomib Consolidation after Nonmyeloablative Allogeneic Stem Cell Transplantation Leads to a High Incidence of Immunophenotypic Complete Response in Young and/or High-Risk Multiple Myeloma Patients. <i>Blood</i> , 2016, 128, 2306-2306.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Potential Targeting Ph+ Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity. <i>Blood</i> , 2016, 128, 2909-2909.	0.6	2
38	Tandem Autologous Followed By Nonmyeloablative Allogeneic Transplantation in Relapsed High Risk Follicular Lymphoma Leads to Excellent Long Term Progression-Free Survival after 8 Years of Follow-up. <i>Blood</i> , 2016, 128, 4677-4677.	0.6	0
39	Early exposure to interleukin-21 limits rapidly generated anti-EBV Epstein-Barr virus T-cell line differentiation. <i>Cytotherapy</i> , 2015, 17, 496-508.	0.3	16
40	Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen. <i>Blood</i> , 2015, 126, 4391-4391.	0.6	3
41	Disruption of the Peripheral Lymphoid Niche Contributes to Lymphopenia in CML Patients Undergoing Imatinib Treatments. <i>Blood</i> , 2015, 126, 5165-5165.	0.6	0
42	The Impact of Graft-Versus-Host Disease on Dendritic Cell Homeostasis and Their Potential Use As Biomarker to Predict the Severity of Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2015, 126, 3149-3149.	0.6	0
43	Phase I Study of Non-Engrafting Allogeneic, Mismatched, Unmanipulated Peripheral Blood Mononuclear Cell Infusions to Treat Poor-Prognosis Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2562-2562.	0.6	1
44	Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML. <i>Blood</i> , 2015, 126, 53-53.	0.6	0
45	Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment. <i>Blood Reviews</i> , 2014, 28, 249-261.	2.8	16
46	Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. <i>Science</i> , 2014, 345, 1509-1512.	6.0	470
47	Endogenous growth factors secreted by mesenchymal stromal cells can be used to guide tissue regeneration. <i>Experimental Hematology</i> , 2014, 42, S48.	0.2	0
48	Selective Photodepletion of Recipient-Alloreactive T-Cells Enables Safe and Efficacious Haploidentical HSCT: Initial Results from a Phase 2 Trial in Patients with AML, ALL, and MDS. <i>Blood</i> , 2014, 124, 314-314.	0.6	3
49	Selective Depletion of Recipient-Alloreactive T-Cells While Retaining Viral-Specific and Memory T-Cells Enables Safe and Efficacious Haplo-Identical HSCT. <i>Blood</i> , 2014, 124, 2490-2490.	0.6	0
50	MiR-300 Acts As a Tumor Suppressor in Ph+ Progenitors By Modulating the JAK2-SET/PP2A/ β -Catenin Interplay. <i>Blood</i> , 2014, 124, 4529-4529.	0.6	0
51	Pneumatosis Coli Associated to Severe Intestinal Graft Versus Host Disease Following Hematopoietic Cell Transplantation: Risk Factors and Dismal Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S333.	2.0	1
52	Safety and Cost-Effectiveness of Outpatient Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 547-551.	2.0	60
53	Implantation of CD133+ Stem Cells in Patients Undergoing Coronary Bypass Surgery: IMPACT-CABG Pilot Trial. <i>Canadian Journal of Cardiology</i> , 2013, 29, 441-447.	0.8	29
54	Transplantation of Mesenchymal Stem Cells Promotes Tissue Regeneration in a Glaucoma Model Through Laser-Induced Paracrine Factor Secretion and Progenitor Cell Recruitment. <i>Stem Cells</i> , 2013, 31, 1136-1148.	1.4	115

#	ARTICLE	IF	CITATIONS
55	PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. <i>Journal of Clinical Investigation</i> , 2013, 123, 4144-4157.	3.9	192
56	High Progression-Free Survival At 10 Years After Tandem Autologous/Nonmyeloablative Allogeneic Transplants For Multiple Myeloma In a Cohort Of 93 Patients: Impact Of Disease Remission Status At Transplant and Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2013, 122, 3353-3353.	0.6	1
57	Pre-Transplant Remission Status and Peripheral Blood Stem Cell Graft Contribute To Long-Term Outcome After Myeloablative Sibling-Donor Allogeneic Transplant For Multiple Myeloma. <i>Blood</i> , 2013, 122, 5541-5541.	0.6	0
58	Distinct but phenotypically heterogeneous human cell populations produce rapid recovery of platelets and neutrophils after transplantation. <i>Blood</i> , 2012, 119, 3431-3439.	0.6	23
59	Selective T-Cell Depletion for Haplotype-Mismatched Allogeneic Stem Cell Transplantation. <i>Seminars in Oncology</i> , 2012, 39, 674-682.	0.8	52
60	Tandem Autologous+Allogeneic Nonmyeloablative Sibling Transplantation in Relapsed Follicular Lymphoma Leads to Impressive Progression-Free Survival with Minimal Toxicity. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 951-957.	2.0	23
61	Individual and synergistic cytokine effects controlling the expansion of cord blood CD34+ cells and megakaryocyte progenitors in culture. <i>Cytotherapy</i> , 2011, 13, 467-480.	0.3	37
62	Incidence and Prognostic Value of Eosinophilia in Chronic Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1673-1678.	2.0	27
63	Next-generation leukemia immunotherapy. <i>Blood</i> , 2011, 118, 2951-2959.	0.6	65
64	Reduction in Incidence of Severe Infections by Transplantation of High Doses of Haploidentical T Cells Selectively Depleted of Alloreactive Units. <i>Blood</i> , 2011, 118, 3020-3020.	0.6	5
65	Screen for Small Molecules Capable of Expanding Human Hematopoietic Stem Cell Ex Vivo. <i>Blood</i> , 2011, 118, 1919-1919.	0.6	0
66	A Canadian Expanded Access Trial of Oral Nilotinib in Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase. <i>Blood</i> , 2011, 118, 4437-4437.	0.6	0
67	COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133+ Bone Marrow Stem Cells to Placebo in Patients After Acute Myocardial Infarction and Left Ventricular Dysfunction: Study Rationale and Design. <i>Journal of Cardiovascular Translational Research</i> , 2010, 3, 153-159.	1.1	55
68	BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment. <i>Blood</i> , 2010, 116, 515-515.	0.6	14
69	The BCR-ABL1-Regulated hnRNP A1, hnRNP E2, and hnRNP K Are Differentially Expressed Between CD34+ and CD34+/CD38- Ph+ Cells, and After Blastic Transformation of CML.. <i>Blood</i> , 2010, 116, 1222-1222.	0.6	0
70	Novel Photodepletion Strategy to Preserve and Expand Tregs While Eliminating CD4+ Effector T Cells From Patients with Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2010, 116, 353-353.	0.6	0
71	An automated system for delivery of an unstable transcription factor to hematopoietic stem cell cultures. <i>Biotechnology and Bioengineering</i> , 2009, 103, 402-412.	1.7	11
72	Skewing of X-inactivation ratios in blood cells of aging women is confirmed by independent methodologies. <i>Blood</i> , 2009, 113, 3472-3474.	0.6	90

#	ARTICLE	IF	CITATIONS
73	Graft-versus-Host Disease Prophylaxis with Tacrolimus and Mycophenolate Mofetil in HLA-Matched Nonmyeloablative Transplant Recipients Is Associated with Very Low Incidence of GVHD and Nonrelapse Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 919-929.	2.0	40
74	FTY720 but Not Its Immunosuppressive Phosphorylated Form FTY720-P Exerts Anti-Leukemic Activity towards Ph(+) and Ph(âˆ“) Myeloproliferative Disorders through Reactivation of the PP2A Tumor Suppressor.. <i>Blood</i> , 2009, 114, 3259-3259.	0.6	3
75	First Line Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma (MCL).. <i>Blood</i> , 2009, 114, 3366-3366.	0.6	2
76	Tandem Autologous-Allogeneic Nonmyeloablative Sibling Transplant in Relapsed Follicular Lymphoma Leads to Impressive Progression Free Survival with Minimal Toxicity.. <i>Blood</i> , 2009, 114, 50-50.	0.6	1
77	Haploidentical Stem Cell Transplantation: High Doses of Alloreactive-T Cell Depleted Donor Lymphocytes Administered Post-Transplant Decrease Infections and Improve Survival without Causing Severe Gvhd.. <i>Blood</i> , 2009, 114, 512-512.	0.6	9
78	Collagen and Elastin Degradation Products as Potential Biomarkers for Chronic Graft-Versus-Host Disease (cGVHD).. <i>Blood</i> , 2009, 114, 1156-1156.	0.6	0
79	Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors.. <i>Blood</i> , 2009, 114, 855-855.	0.6	0
80	Targeting the Oncogene eIF4E with Ribavirin: A Novel Therapeutic Avenue in Acute Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 2085-2085.	0.6	1
81	High Dose Valacyclovir Is Highly Effective to Prevent Cytomegalovirus and Other Herpes Viruses Viremia After Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 1140-1140.	0.6	0
82	Hb Montreal II: A Novel Elongated Î²-Globin Variant Caused by a Frameshift Mutation [Î² ¹⁴² (âˆ“C)]. <i>Hemoglobin</i> , 2008, 32, 351-359.	0.4	1
83	Graft-Versus-Host Disease (Gvhd) Prophylaxis with Tacrolimus and Mycophenolate Mofetil (MMF) in 131 Matched Sibling Nonmyeloablative (NMA) Transplant Recipients: Long-Term Follow-up Confirms Extremely Low Incidence of Acute (a) Gvhd, High Incidence of Extensive Chronic (c) Gvhd and Favorable Disease Outcome.. <i>Blood</i> , 2008, 112, 1176-1176.	0.6	8
84	Activation of PP2A by FTY720 Inhibits Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34+/CD38âˆ“ Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABLâˆ“ independent Signals. <i>Blood</i> , 2008, 112, 189-189.	0.6	10
85	Tandem Autologous-Nonmyeloablative (NMA) Allogeneic(Allo) Transplant (Tx) in Newly Diagnosed Multiple Myeloma (MM) Leads to Improved Survival When Compared to Conventional Allogeneic Transplant. <i>Blood</i> , 2008, 112, 3299-3299.	0.6	0
86	Prediction of Graft-Versus-Host Disease in Humans by Donor Gene-Expression Profiling. <i>PLoS Medicine</i> , 2007, 4, e23.	3.9	99
87	Endothelial-like Vascular Progenitor Cells (VPCs) from Allogeneic and Autologous Donors: Mobilization Features Distinct from Hematopoietic Progenitors. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 433-439.	2.0	14
88	High Incidence of Invasive Aspergillosis Associated with Intestinal Graft-versus-Host Disease following Nonmyeloablative Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1192-1200.	2.0	66
89	Oral Treatment with PBI-1402 Increases Hemoglobin Level and Red Blood Cell Count: A Novel Approach to Treating Chemotherapy-Induced Anemia.. <i>Blood</i> , 2007, 110, 2211-2211.	0.6	2
90	Deletion of HoxA Genes Inhibits Proliferation and Differentiation of Myeloid Progenitors.. <i>Blood</i> , 2007, 110, 1271-1271.	0.6	3

#	ARTICLE	IF	CITATIONS
91	Synthetic 15-mer Peptide (PCK3145) Derived from Prostate Secretory Protein with In Vitro and In Vivo Activity Against Non-Hodgkin's Lymphoma and Other Hematologic Malignancies.. Blood, 2007, 110, 1388-1388.	0.6	12
92	Anti-Chronic Graft Versus Host Disease Activity Through a Regulatory T Cell Dependent Mechanism after Photodynamic Therapy.. Blood, 2007, 110, 3280-3280.	0.6	0
93	Phase I Clinical Trial of Haplotype Mismatched Myeloablative Stem Cell Transplantation: Higher Doses of Donor Lymphocyte Infusions Depleted of Alloreactive Cells Using ATIR May Improve Outcome without Causing GVHD.. Blood, 2007, 110, 2976-2976.	0.6	0
94	Assessment of Individual Characteristics on the Pharmacokinetics of Oral Busulfan in Adults Patients Undergoing Hematopoietic Stem-Cell Transplantation.. Blood, 2007, 110, 1993-1993.	0.6	0
95	Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation. Experimental Hematology, 2006, 34, 107-114.	0.2	13
96	FTY720, a New and Alternative Strategy for Treating Blast Crisis CML and Ph1 ALL Patients.. Blood, 2006, 108, 288-288.	0.6	2
97	Phase I Clinical Study of Donor Lymphocyte Infusion Depleted of Alloreactive T Cells after Haplotype Mismatched Myeloablative Stem Cell Transplantation To Limit Infections and Malignant Relapse without Causing GVHD.. Blood, 2006, 108, 309-309.	0.6	6
98	Oral Administration of PBI-1402 Significantly Reduces Erythropenia and Accelerates Peripheral Blood Recovery in Myeloablated Mice Post Transplantation.. Blood, 2006, 108, 3201-3201.	0.6	1
99	PBI-1402: A Low Molecular Weight Synthetic Hematopoietic Growth Stimulant.. Blood, 2006, 108, 4222-4222.	0.6	2
100	PBI-1402: A Non-Toxic Immunorestorative Small Molecule for the Treatment of Anemia.. Blood, 2006, 108, 4224-4224.	0.6	1
101	PBI-1402: A New Candidate for the Treatment of Anemia.. Blood, 2006, 108, 4223-4223.	0.6	2
102	Molecular and Pharmacologic Suppression of MAPK Activity Rescues Differentiation of BCR/ABL+ Myeloid Progenitors by Releasing C/EBPa from the Inhibitory Effect of hnRNP E2.. Blood, 2006, 108, 2240-2240.	0.6	0
103	Ectopic Expression of Mutated HOXB4 Proteins with Increased Intracellular Stability Affects Both Long and Short Term Hematopoietic Reconstitution.. Blood, 2006, 108, 3183-3183.	0.6	0
104	Ex Vivo Expansion of Human SCID-Repopulating Cells Using Recombinant TAT-HOXB4 Protein.. Blood, 2005, 106, 3159-3159.	0.6	1
105	A Phase I Study with Long-Term Follow-Up of Autologous Stem Cell Transplantation Using Photodynamic Treatment of Marrow Grafts for Relapsed/Refractory Acute Leukemia.. Blood, 2005, 106, 2201-2201.	0.6	0
106	Control of Cell Death Levels Using Th9402-Based PDT Treatment on Fresh PBMC, and Potential Application to Patients with cGvHD.. Blood, 2005, 106, 5258-5258.	0.6	0
107	Mobilization of Endothelial Progenitor Cells in Autologous and Allogeneic Peripheral Blood Stem Cell Grafts.. Blood, 2005, 106, 4231-4231.	0.6	0
108	Specific Elimination of Alloreactive T Lymphocytes Using Photodynamic Therapy Prevents GVHD and Enables Rapid Immune Reconstitution.. Blood, 2004, 104, 4987-4987.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Defective Production of Myeloid Dendritic Cells Results from Skewing of Chronic Myelogenous Leukemia Progenitors.. Blood, 2004, 104, 4700-4700.	0.6	0
110	Potential TH9402-Based ECP Treatment for cGvHD Patients.. Blood, 2004, 104, 5119-5119.	0.6	0
111	Preferential Induction of B Cell Apoptosis Using Photodynamic Therapy.. Blood, 2004, 104, 4643-4643.	0.6	0
112	Recombinant TAT-HOXB4 Protein Promotes Ex Vivo Expansion of Primitive Human Hematopoietic Cells.. Blood, 2004, 104, 2855-2855.	0.6	0
113	Evidence for adequate thymic function but impaired naive T-cell survival following allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease. Blood, 2003, 102, 4600-4607.	0.6	79
114	P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells. Blood, 2002, 100, 375-382.	0.6	79
115	Oncogenic interaction between BCR-ABL andNUP98-HOXA9 demonstrated by the use of an in vitro purging culture system. Blood, 2002, 100, 4177-4184.	0.6	50
116	Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nature Medicine, 2001, 7, 789-794.	15.2	173
117	Relapse after bone marrow transplantation: evidence for distinct immunological mechanisms between adult and paediatric populations. British Journal of Haematology, 2000, 109, 130-137.	1.2	14
118	The Effect of Graft-versus-Host Disease on T Cell Production and Homeostasis. Journal of Experimental Medicine, 1999, 189, 1329-1342.	4.2	98
119	Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nature Genetics, 1999, 23, 166-175.	9.4	1,036
120	Purging of Leukemia Cells with a Photodynamic. Leukemia and Lymphoma, 1998, 30, 50-50.	0.6	2
121	Flow cytometric evaluation of leukocyte subpopulations in the follicular fluids of infertile patients. Fertility and Sterility, 1996, 65, 1135-1140.	0.5	62
122	Allogeneic bone marrow transplantation following busulfan–cyclophosphamide with or without etoposide conditioning regimen for patients with acute lymphoblastic leukaemia. British Journal of Haematology, 1993, 85, 706-713.	1.2	12
123	Cytogenetic characterization of primary refractory anemia. American Journal of Hematology, 1992, 41, 241-248.	2.0	8
124	Negative Regulation of Zap70 by Lck Forms the Mechanistic Basis of Differential Expression in CD4 and CD8 T Cells. Frontiers in Immunology, 0, 13, .	2.2	1